Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Total Neoadjuvant Therapy Versus Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: A Multi-Institutional Real-World Study.
Şenocak Taşçı E, Mutlu AU, Saylık O, Ölmez ÖF, Bilici A, Sünger E, Sütçüoğlu O, Çakmak Öksüzoğlu ÖB, Özdemir N, Akdoğan O, Bayoğlu İV, Majidova N, Güren AK, Özen Engin E, Hacıbekiroğlu İ, Er Ö, Dane F, Bozkurt M, Turan Canbaz E, Erdamar S, Aytaç E, Özer L, Yıldız İ. Şenocak Taşçı E, et al. Among authors: er o. Cancers (Basel). 2024 Sep 21;16(18):3213. doi: 10.3390/cancers16183213. Cancers (Basel). 2024. PMID: 39335184 Free PMC article.
Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours-results from a Turkish multi-centre study.
Olmez OF, Bilici A, Er O, Bisgin A, Sevinc A, Akman T, Uslu R, Mandel NM, Yalcin S, Teomete M, Gorumlu G, Demir A, Namal E, Alici S, Selcukbiricik F, Bavbek S, Paksoy F, Basaran G, Ozer L, Sener N, Harputluoglu H; TUMPACT Study Group. Olmez OF, et al. Among authors: er o. Jpn J Clin Oncol. 2024 May 7;54(5):562-568. doi: 10.1093/jjco/hyae002. Jpn J Clin Oncol. 2024. PMID: 38271177
Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.
Taşçı EŞ, Oyan B, Sönmez Ö, Mutlu AU, Atcı MM, Sakin A, Öner İ, Çınkır HY, Eryılmaz MK, Çağlayan D, Balçık OY, Paksoy N, Karabulut S, Salim DK, Bilir C, Özen M, Özçelik M, Arıcan A, Akagündüz B, İnal A, Aydın D, Özer L, Gülmez A, Turhal NS, Esen SA, Algın E, Akbaş S, İriağaç Y, Şakalar T, Ünal Ç, Er Ö, Seçmeler Ş, Bozkurt M. Taşçı EŞ, et al. Among authors: er o. BMC Cancer. 2024 Jan 23;24(1):114. doi: 10.1186/s12885-024-11863-0. BMC Cancer. 2024. PMID: 38262962 Free PMC article. No abstract available.
Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.
Taşçı EŞ, Oyan B, Sönmez Ö, Mutlu AU, Atcı MM, Sakin A, Öner İ, Çınkır HY, Eryılmaz MK, Çağlayan D, Balçık OY, Paksoy N, Karabulut S, Salim DK, Bilir C, Özen M, Özçelik M, Arıcan A, Akagündüz B, İnal A, Aydın D, Özer L, Gülmez A, Turhal NS, Esen SA, Algın E, Akbaş S, İriağaç Y, Şakalar T, Ünal Ç, Er Ö, Seçmeler Ş, Bozkurt M. Taşçı EŞ, et al. Among authors: er o. BMC Cancer. 2024 Jan 2;24(1):16. doi: 10.1186/s12885-023-11783-5. BMC Cancer. 2024. PMID: 38166764 Free PMC article.
The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study.
Guven DC, Aykan MB, Muglu H, Bayram E, Helvaci K, Dursun B, Celayir M, Chelebiyev E, Nayir E, Erman M, Sezer A, Urun Y, Demirci U, Er O, Disel U, Bilici A, Arslan C, Karadurmus N, Kilickap S. Guven DC, et al. Among authors: er o. Cancer Med. 2024 Jan;13(1):e6869. doi: 10.1002/cam4.6869. Epub 2023 Dec 22. Cancer Med. 2024. PMID: 38140782 Free PMC article.
175 results